Share on StockTwits

Epizyme (NASDAQ:EPZM) EVP Robert A. Copeland unloaded 20,000 shares of the stock on the open market in a transaction dated Monday, June 23rd. The stock was sold at an average price of $28.42, for a total value of $568,400.00. Following the completion of the sale, the executive vice president now directly owns 5,305 shares of the company’s stock, valued at approximately $150,768. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Epizyme (NASDAQ:EPZM) traded up 0.21% on Wednesday, hitting $28.27. The stock had a trading volume of 181,782 shares. Epizyme has a 52 week low of $18.10 and a 52 week high of $45.72. The stock’s 50-day moving average is $24.43 and its 200-day moving average is $26.11. The company’s market cap is $929.7 million.

Epizyme (NASDAQ:EPZM) last announced its earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.25. On average, analysts predict that Epizyme will post $-1.78 earnings per share for the current fiscal year.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.